MERTK receptor tyrosine kinase: A novel therapeutic target for liver fibrosis

MERTK受体酪氨酸激酶：肝纤维化的新治疗靶点

• 批准号: nhmrc : 1107178
• 负责人: Prof Christopher Liddle
• 金额: $ 59.92万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/mertk-receptor-tyrosine-liver-fibrosis/662965
• 关键词: MERTK; receptor; tyrosine; kinase; novel

Hepatic fibrosis is the principal cause of liver-related morbidity and mortality, for which there are no effective therapies. Thus, there is an urgent and unmet need to identify new targets to treat liver fibrosis. We have demonstrated for the first time, that liver fibrosis correlates with elevated hepatic expression of MERTK, a receptor tyrosine kinase. This project will explore whether MERTK function can be exploited to target and reverse liver fibrosis

肝纤维化是肝脏相关疾病发病率和死亡率的主要原因，目前尚无有效的治疗方法。因此，迫切需要鉴定治疗肝纤维化的新靶标。我们首次证明了肝纤维化与MERTK（一种受体酪氨酸激酶）的肝表达升高相关。该项目将探索MERTK功能是否可以用于靶向和逆转肝纤维化